TRDA
Entrada Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Price History
Fundamentals
| Market Cap | $294.45M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.33 |
| EPS (TTM) | $-4.00 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -95.70% |
| ROE | -48.28% |
| Debt/Equity | 18.37 |
| Recommendation | None |
| Analyst Target | $18.75 |
| Analysts | 4 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 71.1 |
| Beta | -0.26 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $16.45 |
| 52-Week Low | $4.93 |
| 50-Day Avg | $8.46 |
| 200-Day Avg | $9.53 |
| Avg Volume | 394.6K |
| Volume | 1.6K |
Performance Analysis
BEARISHTRDA is flashing more cautionary signals — investors should monitor closely.
Recent News
Last updated: Jul 02, 2026 13:34 UTC
Back to Screener Export Report